武汉科前生物股份有限公司 关于 2025 年"提质增效重回报"专项行动方案的半 年度评估报告 基于对公司未来发展前景的信心，为践行"科技创造价值、科前 回报社会"发展理念，强化市值管理和实践，充分发挥上市公司平台 作用，引导公司价值合理回归，促进公司高质量发展，武汉科前生物 股份有限公司（下称"公司"）于 2025 年 4 月 29 日发布《关于 2024 年度"提质增效重回报"专项行动方案的评估报告暨 2025 年度"提 质增效重回报"专项行动方案》。2025 年上半年，公司积极开展和 落实相关工作，现将 2025 年半年度具体落实情况报告如下： 一、坚持创新引领发展，不断增强公司核心竞争力 公司持续加大研发投入，加快新型研发平台的建设，构建 CHO、 mRNA 疫苗等新型技术平台，支撑亚单位、基因载体疫苗等产品研发； 持续推进核心工艺技术的升级及应用，布局无针注射等新型给药方式 用的产品研发，加快产学研合作，加快新产品推出进度，不断完善服 务方案，坚持产品创新、服务创新、技术创新，提升技术优势和产品 品牌优势。2025 年上半年，公司研发费用为 4,549.75 万元，获得新 兽药证书 6 项，申请获得 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、监事会会议召开情况 武汉科前生物股份有限公司（下称"公司"）于 2025 年 8 月 24 日以现场表决的形式召开第四届监事会第十三次会议（以下简称"本 次会议"）。本次会议通知于 2025 年 8 月 14 日以邮件、电话的方式 向各位监事发出，本次会议由监事会主席吴斌先生主持，本次会议应 参与表决监事 3 人，实际参与表决监事 3 人。本次会议的召集、召开 程序均符合《公司法》《证券法》等法律、法规和规范性文件以及《公 司章程》的规定。 二、监事会会议审议情况 经与会监事审议，作出决议如下： （一）审议通过《关于公司<2025 年半年度报告>及其摘要的议 案》 监事会认为：2025 年半年度报告的编制和审议程序符合相关法 律法规、《公司章程》及公司管理制度的有关规定。报告的内容与格 证券代码：688526 证券简称：科前生物 公告编号：2025-043 武汉科前生物股份有限公司 第四届监事会第十三次会议决议公告 监事会认为：公司按照募集资金存放与使用的相关法律法规和 ...

Core Viewpoint - The company, Keqian Bio (688526.SH), reported a significant increase in both revenue and net profit for the first half of the year, indicating strong operational performance and growth potential [1] Financial Performance - The company achieved operating revenue of 487.29 million yuan, representing a year-on-year increase of 21.67% [1] - The net profit attributable to the parent company was 219.90 million yuan, reflecting a year-on-year increase of 44.09% [1]

武汉科前生物股份有限公司2025 年半年度报告 公司代码：688526 公司简称：科前生物 武汉科前生物股份有限公司 2025 年半年度报告 1 / 191 武汉科前生物股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 报告期内不存在对公司生产经营产生实质性影响的重大风险，公司已在报告中详细描述可能 存在的相关风险，敬请查阅"第三节管理层讨论与分析"之"四、风险因素"部分内容，敬请投 资者注意投资风险。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人陈慕琳、主管会计工作负责人钟鸣及会计机构负责人（会计主管人员）陈婵姹 声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的公司未来经营计划、发展战略、预测等前瞻性陈 ...

Market Overview - On August 25, the animal health sector rose by 1.47%, led by Shenlian Biological, while the Shanghai Composite Index closed at 3883.56, up 1.51%, and the Shenzhen Component Index closed at 12441.07, up 2.26% [1]. Stock Performance - Shenlian Biological (688088) closed at 14.50, with a significant increase of 13.81% and a trading volume of 521,000 shares, amounting to 723 million yuan [1]. - Other notable stocks included: - KQ Biological (688526) at 18.10, up 2.67% [1]. - Dayu Biological (871970) at 10.25, up 1.18% [1]. - Huisheng Biological (300871) at 23.75, up 0.93% [1]. - Ruip Biological (300119) at 23.48, up 0.86% [1]. - Jinhai Biological (002688) at 7.31, up 0.55% [1]. Capital Flow - The animal health sector experienced a net outflow of 40.13 million yuan from institutional investors, while retail investors saw a net outflow of 60.97 million yuan. Conversely, speculative funds had a net inflow of 101 million yuan [2]. Individual Stock Capital Flow - Shenlian Biological had a net inflow of 35.39 million yuan from institutional investors, while retail investors faced a net outflow of 74.83 million yuan [3]. - Other stocks with notable capital flows included: - Pulaike (603566) with a net inflow of 3.28 million yuan from institutional investors and a net outflow of 9.68 million yuan from retail investors [3]. - Huisheng Biological (300871) had a net inflow of 2.55 million yuan from institutional investors but a net outflow of 13.77 million yuan from retail investors [3].

人民财讯8月25日电，科前生物(688526)8月25日晚间披露2025年半年报，上半年实现营业收入4.87亿 元，同比增长21.67%；归母净利润2.2亿元，同比增长44.09%；基本每股收益0.47元。 ...

Core Insights - The company reported a revenue of 487 million yuan for the first half of the year, representing a year-on-year growth of 21.67% [1] - The net profit attributable to shareholders of the listed company was 220 million yuan, showing a year-on-year increase of 44.09% [1] - The basic earnings per share were 0.47 yuan [1]

Investment Rating - Industry rating: Outperform the market (maintained rating) [9] Core Insights - The pet industry is experiencing significant growth, with the Asia Pet Expo showcasing over 2,600 exhibitors and 20,000 brands, indicating a thriving market driven by globalization and innovation [2][13] - China's pet food exports have shown continuous growth, with 201,000 tons exported from January to July 2025, reflecting a year-on-year increase of 6.64% [14] - The pig farming sector is facing challenges, with the average pig price at 13.82 yuan/kg, a decrease of 3.63% from the previous week, and the average weight of pigs reaching a historical high [15][16] - The dairy sector is poised for a recovery, with the original milk price expected to rebound as production capacity decreases after a prolonged period of losses [17][18] - The poultry sector is focusing on breeding gaps, with a significant decline in the import of breeding chickens due to avian influenza concerns, which may impact future supply [19][20] - The planting sector emphasizes food security and the importance of biotechnology, with a focus on high-yield and resilient crop varieties [25] - The feed sector is recommended for investment, particularly in companies like Haida Group, which is expected to benefit from market recovery and increased market share [26] Summary by Sections Pet Sector - The Asia Pet Expo has reached a record scale of 310,000 square meters, highlighting the industry's vitality and innovation potential [2][13] - Pet food exports from China have increased, with a total of 201,000 tons exported in the first seven months of 2025, showing a year-on-year growth of 6.64% [14] - Recommended companies include pet food brands like Guibao Pet, Zhongchong Co., and Petty Co. [14] Pig Sector - The average pig price is currently at 13.82 yuan/kg, with a year-to-date low in profitability for pig farming [15][16] - The average weight of pigs is at a historical high, indicating supply pressures [15] - Recommended companies include leading pig farming firms such as Wens Foodstuffs Group and Muyuan Foods [16] Dairy Sector - Yuran Dairy reported stable performance with a revenue of 10.3 billion yuan, showing a year-on-year growth of 2.3% [17] - The dairy industry is expected to see a recovery as production capacity decreases [18] - Recommended companies include Yuran Dairy and China Shengmu Organic Milk [18] Poultry Sector - The poultry sector is facing challenges with breeding imports, particularly for white chickens, due to avian influenza [19][20] - Recommended companies include Shennong Development and Yisheng Livestock [20] Planting Sector - The focus is on food security and biotechnology, with an emphasis on high-yield and resilient crop varieties [25] - Recommended companies include Longping High-Tech and Dabeinong Technology Group [25] Feed Sector - Haida Group is highlighted as a key investment opportunity due to its increasing market share and performance [26] - The animal health sector is also recommended, particularly companies like Kexin Biological [27]

Market Overview - The animal health sector experienced a decline of 0.76% on August 22, with Yongshun Biological leading the drop [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Individual Stock Performance - Yongshun Biological (code: 839729) closed at 11.18, down 4.36% with a trading volume of 91,600 shares and a turnover of 102 million yuan [1] - Dayu Biological (code: 871970) closed at 10.13, down 2.78% with a trading volume of 32,700 shares and a turnover of 33.49 million yuan [1] - Shunlian Biological (code: 688098) closed at 12.74, down 2.00% with a trading volume of 317,600 shares and a turnover of 412 million yuan [1] - Other notable declines include Xianfeng Holdings (code: 002141) down 1.79% and Jinhai Biological (code: 002688) down 1.36% [1] Capital Flow Analysis - The animal health sector saw a net outflow of 74.19 million yuan from institutional investors, while retail investors had a net inflow of 91.60 million yuan [1] - Key stocks with significant capital flow include: - Huisheng Biological (code: 300871) with a net outflow of 9.62 million yuan from institutional investors [2] - Kexin Biological (code: 688526) with a net inflow of 7.28 million yuan from institutional investors [2] - ST Lvkang (code: 002868) had a net outflow of 3.99 million yuan from institutional investors but a net inflow of 3.77 million yuan from retail investors [2]

Market Overview - The Shanghai Composite Index reached 3800 points, marking a ten-year high, with the ChiNext Index rising over 3% and the STAR Market Index soaring more than 8% [3] - A total of 2803 stocks rose, with 79 hitting the daily limit up, while 2396 stocks declined [3][4] - The total trading volume was approximately 25,788.42 billion, with a total of 5426 stocks traded [4] Sector Performance - Financial stocks, led by brokerages, showed strong performance, with Everbright Securities and Xinda Securities hitting the daily limit up, and Zhinancai rising over 10% to a new high [5] - The semiconductor sector experienced a collective surge, with stocks like Cambrian and Zhaoyi Innovation hitting the daily limit up, and SMIC rising over 10% [7] Key Stocks - Notable performers in the financial sector included: - Everbright Securities (601788) up 10.01% at 20.78 - Xinda Securities (601059) up 6.6% at 19.72 - GF Securities (000776) up 7.27% at 22.42 [6] - In the semiconductor sector, key stocks included: - Cambrian (288526) up 20% at 1243.20 - Zhaoyi Innovation (603986) up 10% at 150.88 [8] Catalysts for Semiconductor Surge - The surge in the semiconductor sector is attributed to two main factors: 1. The update of the DeepSeek model to version V3.1, which is expected to support FP8 precision and domestic chips, indicating a boost for the domestic computing power sector [9] 2. Nvidia's halt in the production of the H20 chip, leading to increased investor confidence in Chinese AI chip manufacturers as alternative suppliers [10]